Stocks of the Hour: Golden Deeps, Noxopharm, Echo IQ
A snapshot of the stocks on the move, featuring Golden Deeps (ASX:GED), Noxopharm (ASX:NOX) and Echo IQ (ASX:EIQ).
Watch Now
Noxopharm Limited
Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company.
The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy.
ASX Code
NOX
Spotlight Videos
Stocks of the Hour: Whitehaven Coal, Paradigm Biopharma, Noxopharm, Liontown Resources
A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Biopharmaceuticals (ASX:PAR), Noxopharm (ASX:NOX) and Liontown Resources (ASX:LTR).
Watch Now
Stocks of the Hour: Noxopharm, Redstone Resources, Lake Resources
A snapshot of the stocks on the move, featuring Noxopharm (ASX:NOX), Redstone Resources (ASX:RDS) and Lake Resources (ASX:LKE).
Watch Now
Noxopharm (ASX: NOX) – Webinar Presentation
Presenter - Graham Kelly - CEO & MD - Noxopharm is a clinical stage drug development company.
Watch Now
Noxopharm Study Finds its Drug Improves Prostate Cancer Survival Rates
Noxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. The company's CEO Dr Graham Kelly tells us more.
Watch Now
